Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.42 |
| ▸ | CDK2AP1 | O14519 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562936 | 0.98 | USP30 (0.55) | USP30CHEK1GABRA5ACKR3PARP1 | |
| SCHEMBL5001102 | 0.92 | USP30 (0.43) | USP30CHEK1PARP1PBKCDK2AP1 | |
| SCHEMBL5554768 | 0.90 | CHEK1 (0.51) | CHEK1CDK2AP1 | |
| SCHEMBL5556375 | 0.87 | CHEK1 (0.54) | USP30CHEK1CDK2AP1 | |
| SCHEMBL4211957 | 0.87 | CHEK1 (0.54) | USP30CHEK1GABRA5PARP1PBK | |
| SCHEMBL4213212 | 0.85 | CHEK1 (0.52) | USP30CHEK1PARP1PBKCDK2AP1 | |
| Trifluoroacetic Acid SCHEMBL4223931 | 0.85 | CHEK1 (0.51) | USP30CHEK1GABRA5ACKR3PARP1 | |
| SCHEMBL4210048 | 0.84 | CHEK1 (0.44) | CHEK1CDK2AP1 | |
| SCHEMBL1563534 | 0.84 | CHEK1 (0.68) | USP30CHEK1CDK2AP1 | |
| SCHEMBL1562875 | 0.84 | USP30 (0.57) | USP30CHEK1ACKR3PARP1PBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305671-A1 | Thiophene and thiazole derivatives as CHK1 inhibitors | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |